How Long Should You Stay on MAT? The Evidence Behind Long-Term Medication for Addiction
There is no predetermined right time to stop MAT. NIDA and SAMHSA recommend continuing as long as it provides benefit. The evidence for long-term medication, risks of premature tapering, and how to make the decision with your provider.
"How long will I need to be on this?" It's the first question most patients ask when starting medication-assisted treatment — and the answer their doctor gives can determine whether they stay in recovery or relapse. The short answer from every major medical authority is the same: there is no predetermined right time to stop MAT. The right duration is however long it keeps you alive, stable, and in recovery.
Yet pressure to taper off MAT comes from everywhere — family members who think you're "still on drugs," friends in 12-step programs who equate medication with using, employers who question why you still need it, and even some treatment providers who set arbitrary timelines. This pressure kills people. According to NIDA, premature discontinuation of MAT is associated with dramatically increased relapse and overdose death rates.
This guide presents the evidence — not opinions — on MAT duration, explains why the "taper as fast as possible" mindset is medically dangerous, and provides a framework for having the tapering conversation with your prescriber when (and if) the time is right. For a comparison of MAT medications, see our Suboxone vs. Vivitrol vs. Methadone guide.
SAMHSA states: "There is no maximum recommended duration of MAT maintenance treatment, and for some patients, MAT treatment may continue indefinitely." NIDA adds that patients who discontinue MAT prematurely have relapse rates and overdose death rates significantly higher than those who continue.
What the Evidence Says About MAT Duration
The research on MAT duration is unambiguous — and it contradicts the cultural pressure to get off medication quickly:
| Duration | Relapse Rate After Discontinuation | Evidence |
|---|---|---|
| Less than 1 month | 80%+ relapse within 1 month of stopping | Short-term detox without MAT continuation has the worst outcomes |
| 1-6 months | 60-70% relapse within 6 months of stopping | Better than no MAT, but premature tapering still carries high risk |
| 6-12 months | 40-50% relapse within 1 year of stopping | Minimum recommended duration by most clinical guidelines |
| 1-2+ years | 20-30% relapse after gradual taper | Longer duration = lower relapse risk, particularly with gradual taper |
| Indefinite (maintenance) | Lowest risk while on medication | NIDA and SAMHSA explicitly support indefinite MAT for patients who benefit |
The pattern is clear: the longer you stay on MAT, the lower your relapse risk when you eventually stop. And for many patients, the optimal duration is indefinite — just as a diabetic may take insulin indefinitely, or a person with hypertension may take blood pressure medication for life.
Why Premature Tapering Is Dangerous
The most dangerous period in a person's recovery is immediately after discontinuing MAT. Here's why:
- Tolerance loss: While on buprenorphine or methadone, your opioid tolerance is maintained at a controlled level. When you taper off, tolerance drops rapidly. If you relapse and use at your previous dose, your body can no longer handle it — this is the primary mechanism of post-MAT overdose death.
- Neurological rebound: MAT medications stabilize opioid receptors that were damaged by addiction. Removing the medication before the brain has fully healed creates a neurochemical crisis — intense cravings, dysphoria, anxiety, and insomnia that overwhelm coping skills.
- Environmental triggers persist: Your triggers — people, places, emotions — don't disappear on a medication timeline. Tapering off MAT while still navigating a triggering environment is like removing a cast while the bone is still healing.
Studies show that the period immediately following MAT discontinuation has the highest overdose death risk of any point in the recovery timeline — higher than active use, higher than the first days of treatment. This is because tolerance drops but the addiction brain pathways remain. If someone relapses after tapering off MAT, their body cannot survive the dose their brain is telling them to take.
When IS It Appropriate to Consider Tapering?
Tapering is not never appropriate — but it should be a carefully evaluated clinical decision, not a response to external pressure. Your prescriber may consider tapering when all of these conditions are met:
- Sustained stability: At least 1-2 years of consistent recovery with no relapses, no missed doses, and stable lifestyle
- Strong recovery foundation: Active support group participation, strong sober social network, ongoing outpatient counseling, and relapse prevention plan in place
- Stable life circumstances: Secure housing, stable employment, supportive relationships, no major life stressors on the horizon
- Co-occurring conditions treated: Depression, anxiety, PTSD are well-managed with non-addictive medications or therapy
- Patient-initiated: The desire to taper comes from the patient — not from family pressure, insurance limitations, or a counselor's ideology. You should never be pressured to stop medication that is keeping you alive.
- Gradual timeline: Successful tapers are measured in months, not weeks. A typical buprenorphine taper reduces dose by 10-25% every 2-4 weeks, with the ability to pause or reverse the taper at any point if symptoms emerge.
The Stigma Problem: "You're Still on Drugs"
Perhaps the biggest barrier to appropriate MAT duration isn't medical — it's cultural. Patients on MAT face stigma from multiple directions:
- Family: "When are you going to be done with that stuff? You're still dependent on something."
- 12-step communities: Some (not all) AA/NA groups consider MAT patients not "truly sober." This drives some patients to discontinue medication against medical advice to feel accepted.
- Employers: Concerns about medication affecting job performance (it doesn't at stable doses — the ADA protects MAT patients from employment discrimination).
- Treatment providers: Some counselors and even some physicians hold outdated beliefs that MAT should be short-term only.
The medical community's position is unambiguous: MAT is medicine, not a drug of abuse. Buprenorphine at a therapeutic dose does not produce euphoria, does not impair function, and allows patients to work, drive, parent, and live normally. No one would tell a diabetic to stop insulin because they've been "stable for a year" — the same logic applies to MAT.
What Each MAT Medication's Taper Looks Like
| Medication | Typical Taper Approach | Timeline |
|---|---|---|
| Buprenorphine (Suboxone) | Reduce dose by 10-25% every 2-4 weeks. The final reductions (below 2mg) are the hardest and should be slowest. Can pause/reverse at any point. | 3-12 months for a comfortable taper |
| Methadone | Reduce by 5-10% every 1-2 weeks. Slower than buprenorphine due to full agonist properties. The lower the dose gets, the slower the reductions should be. | 6-18 months for a safe, gradual taper |
| Vivitrol (naltrexone) | No taper needed — it's an antagonist. Simply stop getting the monthly injection. However, plan for increased vulnerability to cravings and triggers after the last injection wears off (4-6 weeks). | No taper, but plan for post-discontinuation support |
How to Talk to Your Provider About Duration
Whether you want to stay on MAT or explore tapering, the conversation should be collaborative:
Questions to ask your prescriber:
- "Based on my history and current stability, what do you recommend for my MAT duration?"
- "What would need to be in place before we consider tapering?"
- "If we try tapering and I start struggling, can we go back up?"
- "What does the research say about relapse rates after tapering at my current duration?"
- "Are there alternative approaches like transitioning from daily Suboxone to monthly Vivitrol?"
A good prescriber will never pressure you to taper before you're ready. If your provider is pushing discontinuation against your wishes or against clinical guidelines, consider getting a second opinion from another MAT prescriber. Find Indiana MAT providers through our Suboxone directory or methadone clinic locator.
The Bottom Line
MAT saves lives. Stopping MAT prematurely costs lives. The decision about duration should be:
- Evidence-based — guided by research showing longer duration = better outcomes
- Patient-centered — driven by your needs, not external pressure
- Collaborative — made together with your prescriber, not unilaterally
- Reversible — with the ability to increase dose or restart if needed
- Gradual — measured in months, not weeks
If you're on MAT and it's working, keep going. If someone is pressuring you to stop, show them this article. If you want to explore tapering, have the conversation with your provider — not your family, not your AA sponsor, not the internet. Verify your insurance covers ongoing MAT and call 1-800-662-4357 if you need a new provider.